Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.

Autor: Saeed A; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS. Electronic address: asaeed@kumc.edu., Park R; Department of Medicine, College of Medicine, Korea University, Seoul, South Korea., Al-Jumayli M; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS., Al-Rajabi R; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS., Sun W; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS.
Jazyk: angličtina
Zdroj: Clinical colorectal cancer [Clin Colorectal Cancer] 2019 Jun; Vol. 18 (2), pp. 81-90. Date of Electronic Publication: 2019 Feb 27.
DOI: 10.1016/j.clcc.2019.02.005
Abstrakt: Gemcitabine plus cisplatin remains the standard first-line systemic therapy for advanced cholangiocarcinoma and offers a median survival of approximately 1 year. No standard regimens beyond the first line and no targeted or immunotherapy agents are approved yet in this disease. Development of molecular targeted therapy in this heterogenous and relatively rare malignancy continues to be a challenging area. The rapidly growing precision medicine efforts have uncovered the underlying mutational landscape of this lethal disease and paved the way for molecularly oriented clinical trials. The early results from such trials like those exploring IDH and FGFR2 derangements have highlighted its promising potential as alternative therapeutic options. Additionally, advances in cancer immunology have identified certain correlates as biomarkers of response to immune modulatory approaches. For instance, the presence of tumor DNA mismatch repair (MMR) deficiency and/or microsatellite instability (MSI), in 5% to 10% of cholangiocarcinoma, is associated with high rates and durability of responses to immune checkpoint blockade. Beside checkpoint inhibitors, other types of immune therapeutics like peptide and dendritic cell-based vaccines and adoptive cell therapies have been developed and are undergoing active evaluation in cholangiocarcinoma. With further research effort, the integration of tumor molecular profiling in trials exploring targeted immunotherapy will lead to better understanding of the predictive role of various molecular and immune biomarkers and ultimately shine the horizon for this patient population.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: